Macquarie Group Ltd. decreased its stake in shares of Zoetis Inc (NYSE:ZTS) by 3.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 203,875 shares of the company’s stock after selling 7,050 shares during the period. Macquarie Group Ltd.’s holdings in Zoetis were worth $17,440,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. Berman Capital Advisors LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $26,000. Athena Capital Advisors LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $29,000. Resources Investment Advisors Inc. acquired a new stake in Zoetis in the 4th quarter valued at approximately $31,000. Lavaca Capital LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $32,000. Finally, Acima Private Wealth LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $34,000. 90.92% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on ZTS. UBS Group began coverage on Zoetis in a research report on Wednesday, March 20th. They issued a “neutral” rating for the company. SunTrust Banks began coverage on Zoetis in a research report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price objective for the company. Stifel Nicolaus upgraded Zoetis from a “hold” rating to a “buy” rating and raised their price objective for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. BMO Capital Markets raised their price objective on Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research upgraded Zoetis from a “sell” rating to a “hold” rating in a research report on Saturday, February 16th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $98.93.
NYSE ZTS opened at $101.54 on Tuesday. The firm has a market capitalization of $48.20 billion, a PE ratio of 32.44, a PEG ratio of 1.83 and a beta of 0.92. Zoetis Inc has a 52 week low of $77.00 and a 52 week high of $102.47. The company has a quick ratio of 2.46, a current ratio of 3.60 and a debt-to-equity ratio of 2.95.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 14th. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.02. The company had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the firm earned $0.69 EPS. As a group, equities research analysts expect that Zoetis Inc will post 3.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be paid a $0.164 dividend. The ex-dividend date of this dividend is Wednesday, April 17th. This represents a $0.66 annualized dividend and a dividend yield of 0.65%. Zoetis’s dividend payout ratio (DPR) is currently 21.09%.
Zoetis announced that its Board of Directors has approved a share repurchase plan on Wednesday, December 12th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2019/04/02/macquarie-group-ltd-has-17-44-million-stake-in-zoetis-inc-zts.html.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What are retained earnings?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.